Sfoglia per Autore
The promise of liquid biopsy in cancer: A clinical perspective
2015 Cortesi E.; Palleschi M.; Magri V.; Naso G.
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer
2017 Gamucci T.; Mentuccia L.; Natoli C.; Sperduti I.; Cassano A.; Michelotti A.; Di Lauro L.; Sergi D.; Fabi A.; Sarobba M.G.; Marchetti P.; Barba M.; Magnolfi E.; Maugeri-Sacca M.; Rossi E.; Sini V.; Grassadonia A.; Pellegrini D.; Astone A.; Nistico C.; Angelini F.; Vaccaro A.; Pellegrino A.; De Angelis C.; Palleschi M.; Moscetti L.; Bertolini I.; Buglioni S.; Giordano A.; Pizzuti L.; Vici P.
Precision medicine: PI3K targeting in advanced breast cancer
2019 Rocca A.; Melegari E.; Palleschi M.
Ribociclib and endocrine therapy in breast cancer
2019 Rocca A.; Melegari E.; Palleschi M.
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report
2020 Palleschi M.; Maltoni R.; Barzotti E.; Melegari E.; Curcio A.; Cecconetto L.; Sarti S.; Manunta S.; Rocca A.
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
2020 Maltoni R.; Palleschi M.; Ravaioli S.; Tumedei M.M.; Rocca A.; Melegari E.; Altini M.; Puccetti M.; Manunta S.; Bravaccini S.
Are we ready to use TMB in breast cancer clinical practice?
2020 Ravaioli S.; Limarzi F.; Tumedei M.M.; Palleschi M.; Maltoni R.; Bravaccini S.
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter
2020 Bravaccini S.; Ravaioli S.; Tumedei M.M.; Rocca A.; Palleschi M.; Puccetti M.; Parrella P.; Altini M.; Maltoni R.
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?
2020 Maltoni R.; Palleschi M.; Altini M.; Massa I.; Balzi W.; Ravaioli S.; Tumedei M.M.; Rocca A.; Bravaccini S.
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?
2020 Palleschi M.; Maltoni R.; Sarti S.; Melegari E.; Bravaccini S.; Rocca A.
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience
2020 Palleschi M.; Maltoni R.; Ravaioli S.; Vagheggini A.; Mannozzi F.; Fanini F.; Pirini F.; Tumedei M.M.; Barzotti E.; Cecconetto L.; Sarti S.; Manunta S.; Possanzini P.; Fedeli A.; Curcio A.; Altini M.; de Giorgi U.; Rocca A.; Bravaccini S.
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
2021 Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C.; De Giorgi U.
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial
2021 Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magri V, Palleschi M, Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F;
Moving beyond parp inhibition: Current state and future perspectives in breast cancer
2021 Palleschi M.; Tedaldi G.; Sirico M.; Virga A.; Ulivi P.; De Giorgi U.
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
2021 Del Re M.; Omarini C.; Diodati L.; Palleschi M.; Meattini I.; Crucitta S.; Lorenzini G.; Isca C.; Fontana A.; Livi L.; Piacentini F.; Fogli S.; De Giorgi U.; Danesi R.
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 Vernieri C.; Nichetti F.; Lalli L.; Moscetti L.; Giorgi C.A.; Griguolo G.; Marra A.; Randon G.; Rea C.G.; Ligorio F.; Scagnoli S.; De Angelis C.; Molinelli C.; Fabbri A.; Ferraro E.; Trapani D.; Milani A.; Agostinetto E.; Bernocchi O.; Catania G.; Vantaggiato A.; Palleschi M.; Moretti A.; Basile D.; Cinausero M.; Ajazi A.; Castagnoli L.; Vullo S.L.; Gerratana L.; Puglisi F.; La Verde N.; Arpino G.; Rocca A.; Ciccarese M.; Pedersini R.; Fabi A.; Generali D.; Losurdo A.; Montemurro F.; Curigliano G.; Del Mastro L.; Michelotti A.; Cortesi E.; Guarneri V.; Pruneri G.; Mariani L.; De Braud F.
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
2021 Palleschi M.; Scarpi E.; Casadei C.
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor
2021 Palleschi M.; Iaia M.L.; Casadei C.
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
2022 Gianni C.; Palleschi M.; Schepisi G.; Casadei C.; Bleve S.; Merloni F.; Sirico M.; Sarti S.; Cecconetto L.; Di Menna G.; Schettini F.; De Giorgi U.
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
2022 Del Re M.; Omarini C.; Diodati L.; Palleschi M.; Meattini I.; Crucitta S.; Lorenzini G.; Isca C.; Fontana A.; Livi L.; Piacentini F.; Fogli S.; De Giorgi U.; Danesi R.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| The promise of liquid biopsy in cancer: A clinical perspective | Cortesi E.; Palleschi M.; Magri V.; Naso G. | 2015-01-01 | CHINESE JOURNAL OF CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer | Gamucci T.; Mentuccia L.; Natoli C.; Sperduti I.; Cassano A.; Michelotti A.; Di Lauro L.; Sergi D....; Fabi A.; Sarobba M.G.; Marchetti P.; Barba M.; Magnolfi E.; Maugeri-Sacca M.; Rossi E.; Sini V.; Grassadonia A.; Pellegrini D.; Astone A.; Nistico C.; Angelini F.; Vaccaro A.; Pellegrino A.; De Angelis C.; Palleschi M.; Moscetti L.; Bertolini I.; Buglioni S.; Giordano A.; Pizzuti L.; Vici P. | 2017-01-01 | JOURNAL OF CELLULAR PHYSIOLOGY | - | 1.01 Articolo in rivista | Journal Cellular Physiology - 2016 - Gamucci - A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and.pdf |
| Precision medicine: PI3K targeting in advanced breast cancer | Rocca A.; Melegari E.; Palleschi M. | 2019-01-01 | BREAST CANCER RESEARCH AND TREATMENT | - | 1.04 Replica / breve intervento (e simili) | - |
| Ribociclib and endocrine therapy in breast cancer | Rocca A.; Melegari E.; Palleschi M. | 2019-01-01 | THE NEW ENGLAND JOURNAL OF MEDICINE | - | 1.04 Replica / breve intervento (e simili) | - |
| Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report | Palleschi M.; Maltoni R.; Barzotti E.; Melegari E.; Curcio A.; Cecconetto L.; Sarti S.; Manunta S....; Rocca A. | 2020-01-01 | WORLD JOURNAL OF CLINICAL CASES | - | 1.04 Replica / breve intervento (e simili) | - |
| Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer | Maltoni R.; Palleschi M.; Ravaioli S.; Tumedei M.M.; Rocca A.; Melegari E.; Altini M.; Puccetti M....; Manunta S.; Bravaccini S. | 2020-01-01 | CELL TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Are we ready to use TMB in breast cancer clinical practice? | Ravaioli S.; Limarzi F.; Tumedei M.M.; Palleschi M.; Maltoni R.; Bravaccini S. | 2020-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.04 Replica / breve intervento (e simili) | - |
| Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter | Bravaccini S.; Ravaioli S.; Tumedei M.M.; Rocca A.; Palleschi M.; Puccetti M.; Parrella P.; Altin...i M.; Maltoni R. | 2020-01-01 | CLINICAL CANCER RESEARCH | - | 1.04 Replica / breve intervento (e simili) | - |
| Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? | Maltoni R.; Palleschi M.; Altini M.; Massa I.; Balzi W.; Ravaioli S.; Tumedei M.M.; Rocca A.; Bra...vaccini S. | 2020-01-01 | CLINICAL BREAST CANCER | - | 1.04 Replica / breve intervento (e simili) | - |
| Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? | Palleschi M.; Maltoni R.; Sarti S.; Melegari E.; Bravaccini S.; Rocca A. | 2020-01-01 | THE BREAST JOURNAL | - | 1.04 Replica / breve intervento (e simili) | - |
| Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience | Palleschi M.; Maltoni R.; Ravaioli S.; Vagheggini A.; Mannozzi F.; Fanini F.; Pirini F.; Tumedei ...M.M.; Barzotti E.; Cecconetto L.; Sarti S.; Manunta S.; Possanzini P.; Fedeli A.; Curcio A.; Altini M.; de Giorgi U.; Rocca A.; Bravaccini S. | 2020-01-01 | DIAGNOSTICS | - | 1.01 Articolo in rivista | Ki67 and PR in Patients Treated with CDK4 6.pdf |
| The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives | Brighi N.; Conteduca V.; Lolli C.; Gurioli G.; Schepisi G.; Palleschi M.; Mariotti M.; Casadei C....; De Giorgi U. | 2021-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial | Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magri V, Palleschi M, ...Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F; | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Moving beyond parp inhibition: Current state and future perspectives in breast cancer | Palleschi M.; Tedaldi G.; Sirico M.; Virga A.; Ulivi P.; De Giorgi U. | 2021-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-22-07884-v3.pdf |
| Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients | Del Re M.; Omarini C.; Diodati L.; Palleschi M.; Meattini I.; Crucitta S.; Lorenzini G.; Isca C.;... Fontana A.; Livi L.; Piacentini F.; Fogli S.; De Giorgi U.; Danesi R. | 2021-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | - |
| Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) | Vernieri C.; Nichetti F.; Lalli L.; Moscetti L.; Giorgi C.A.; Griguolo G.; Marra A.; Randon G.; R...ea C.G.; Ligorio F.; Scagnoli S.; De Angelis C.; Molinelli C.; Fabbri A.; Ferraro E.; Trapani D.; Milani A.; Agostinetto E.; Bernocchi O.; Catania G.; Vantaggiato A.; Palleschi M.; Moretti A.; Basile D.; Cinausero M.; Ajazi A.; Castagnoli L.; Vullo S.L.; Gerratana L.; Puglisi F.; La Verde N.; Arpino G.; Rocca A.; Ciccarese M.; Pedersini R.; Fabi A.; Generali D.; Losurdo A.; Montemurro F.; Curigliano G.; Del Mastro L.; Michelotti A.; Cortesi E.; Guarneri V.; Pruneri G.; Mariani L.; De Braud F. | 2021-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? | Palleschi M.; Scarpi E.; Casadei C. | 2021-01-01 | BREAST CANCER RESEARCH AND TREATMENT | - | 1.01 Articolo in rivista | - |
| Germline BRCA-mutated metastatic breast cancer with positive hormone receptor | Palleschi M.; Iaia M.L.; Casadei C. | 2021-01-01 | BREAST CANCER RESEARCH AND TREATMENT | - | 1.04 Replica / breve intervento (e simili) | - |
| Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment | Gianni C.; Palleschi M.; Schepisi G.; Casadei C.; Bleve S.; Merloni F.; Sirico M.; Sarti S.; Cecc...onetto L.; Di Menna G.; Schettini F.; De Giorgi U. | 2022-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients | Del Re M.; Omarini C.; Diodati L.; Palleschi M.; Meattini I.; Crucitta S.; Lorenzini G.; Isca C.;... Fontana A.; Livi L.; Piacentini F.; Fogli S.; De Giorgi U.; Danesi R. | 2022-01-01 | ESMO OPEN | - | 1.04 Replica / breve intervento (e simili) | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile